AR018100A1 - POLYPEPTIDES THAT UNDERSTAND AN IMMUNOGENIC PART OF AN ANTIGEN OF M. SOLUBLE TUBERCULOSIS, AND DNA MOLECULES THAT CODIFY SUCH POLYPEPTIDES, EXPRESSION VECTORS THAT UNDERSTAND SUCH MOLECULES OF DNA, CELLS HARDWARE, DIFFERENT MUSCLES - Google Patents

POLYPEPTIDES THAT UNDERSTAND AN IMMUNOGENIC PART OF AN ANTIGEN OF M. SOLUBLE TUBERCULOSIS, AND DNA MOLECULES THAT CODIFY SUCH POLYPEPTIDES, EXPRESSION VECTORS THAT UNDERSTAND SUCH MOLECULES OF DNA, CELLS HARDWARE, DIFFERENT MUSCLES

Info

Publication number
AR018100A1
AR018100A1 ARP990100703A AR018100A1 AR 018100 A1 AR018100 A1 AR 018100A1 AR P990100703 A ARP990100703 A AR P990100703A AR 018100 A1 AR018100 A1 AR 018100A1
Authority
AR
Argentina
Prior art keywords
pro
ala
gly
thr
asp
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/072,967 external-priority patent/US6592877B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR018100A1 publication Critical patent/AR018100A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Se presentan compuestos y métodos para la induccion de la inmunidad protectora contra la tuberculosis. Los compuetos suministrados incluyen polipéptidosque contienen al menos una parte inmunogénica de una o más proteínas de M. tuberculosis y moléculas de ADN que codifican tales polipéptidos. Los citadoscompuestos pueden estar formulados en la forma de vacunas y/o composiciones farmacéuticas para la inmunizacion contra la infeccion de M. tuberculosis, o bienpueden ser utilizados para el diagnostico de la tuberculosis. Como ejemplo de dichos polipéptidos pueden citarse los siguientes: (a) Asp-Pro-Val-Asp-Ala-Val-lle-Asn-Thr-Thr-Cys-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala-Leu; (ID SEQ.Ns 120) (b) Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro-Ala-Pro-Ser; (ID SEQ Ns 121 (c)Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg;(ID SEQ Ns122)(d)Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala-Trp-Gly-Pro; (ID SEQ.Ns 123) (e) Asp-lle-Gly-Ser-Glu-Ser-Thr-Glu-Asp-Gln-Xaa-Ala-Val;(ID SEQ.Ns 124) (f)Ala-Glu-Glu-Ser-lle-Ser-Thr-Xaa-Glu-Xaa-lle-Val-Pro; (ID SEQ.Ns125) (g) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Ala-Ala-Ser-Pro-Pro-Ser:(ID SEQ Ns 126) (h)Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly; (ID SEQ Ns127)(i)Asp-Pro-Ala-Se-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Leu-Thr-Ser-Leu-Leu-Asn-Ser-Leu-Ala-Asp-Pro-Asn-Val-Ser-Phe-ala-Asn; (ID SEQ.Ns 128)(ID.SEQ.Ns 136) (k) Asp--Pro-Asp-Pro-His-Gln-Xaa-Asp-Met-Thr-Lys-Gly-Tyr-Tyr-Pro-Gly-Gly-Arg-Arg-Saa-Phe; (ID SEQ.Ns 129) y (l) Xaa-Tyr-lle-Ala-Tyr-Xaa-Thr-Ala-Gly-lle-Val-Pro-Gly-Lys-lle-Asn-Val-His-Leu-Val; (ID SEQ.Ns 137) donde Xaa puede ser cualquier aminoácido o donde el citado antígeno comprende una secuencia de aminoácidoscodificada por una secuenciade ADN que se selecciona entre el grupo que consiste en las secuencias que se enumeran en ID SEQ.NS 1,1, 4-10, 13-25, 52, 99 y 101los complementos de las citadas secuencias, y las secuencias de ADN que se hibridizan para formar una secuencia que se enumera en ID SEQ.Ns 1,2,4-10, 13-25, 5299, y 101 o un complemento de ellas en condiciones moderadamente severas, comprenden una secuencia de aminoácidos codificad por una secuencia de ADN que seCompounds and methods for inducing protective immunity against tuberculosis are presented. Compounds supplied include polypeptides that contain at least one immunogenic part of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. The said compounds may be formulated in the form of vaccines and / or pharmaceutical compositions for immunization against the infection of M. tuberculosis, or they may be used for the diagnosis of tuberculosis. As an example of such polypeptides, the following may be mentioned: (a) Asp-Pro-Val-Asp-Ala-Val-lle-Asn-Thr-Thr-Cys-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala -Leu; (ID SEQ.Ns 120) (b) Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro-Ala-Pro-Ser; (SEQ ID Ns 121 (c) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg; (SEQ ID Ns122 ) (d) Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala-Trp-Gly-Pro; (ID SEQ.Ns 123) (e) Asp-lle-Gly- Ser-Glu-Ser-Thr-Glu-Asp-Gln-Xaa-Ala-Val; (ID SEQ.Ns 124) (f) Ala-Glu-Glu-Ser-lle-Ser-Thr-Xaa-Glu-Xaa- lle-Val-Pro; (ID SEQ.Ns125) (g) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Ala-Ala-Ser-Pro-Pro-Ser: (SEQ ID Ns 126) (h) Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly; (SEQ ID Ns127) (i) Asp-Pro-Ala- Se-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Leu-Thr-Ser-Leu-Leu-Asn-Ser-Leu-Ala-Asp-Pro-Asn-Val-Ser-Phe- ala-Asn; (ID SEQ.Ns 128) (ID.SEQ.Ns 136) (k) Asp - Pro-Asp-Pro-His-Gln-Xaa-Asp-Met-Thr-Lys-Gly-Tyr-Tyr -Pro-Gly-Gly-Arg-Arg-Saa-Phe; (ID SEQ.Ns 129) and (l) Xaa-Tyr-lle-Ala-Tyr-Xaa-Thr-Ala-Gly-lle-Val-Pro- Gly-Lys-lle-Asn-Val-His-Leu-Val; (ID SEQ.Ns 137) where Xaa can be any amino acid or where said antigen comprises an amino acid sequence encoded by a DNA sequence which is selected from the group consisting of the sequences listed in ID SEQ.NS 1,1, 4-10, 13-25, 52, 99 and 101 the complements of the aforementioned sequences, and the DNA sequences that hybridize to form a sequence that is listed in ID SEQ.Ns 1,2,4-10, 13-25, 5299, and 101 or a complement thereof under moderately severe conditions, comprise an amino acid sequence encoded by a DNA sequence that I know

ARP990100703 1998-02-18 1999-02-23 POLYPEPTIDES THAT UNDERSTAND AN IMMUNOGENIC PART OF AN ANTIGEN OF M. SOLUBLE TUBERCULOSIS, AND DNA MOLECULES THAT CODIFY SUCH POLYPEPTIDES, EXPRESSION VECTORS THAT UNDERSTAND SUCH MOLECULES OF DNA, CELLS HARDWARE, DIFFERENT MUSCLES AR018100A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2519798A 1998-02-18 1998-02-18
US09/072,967 US6592877B1 (en) 1995-09-01 1998-05-05 Compounds and methods for immunotherapy and diagnosis of tuberculosis

Publications (1)

Publication Number Publication Date
AR018100A1 true AR018100A1 (en) 2001-10-31

Family

ID=21824612

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100703 AR018100A1 (en) 1998-02-18 1999-02-23 POLYPEPTIDES THAT UNDERSTAND AN IMMUNOGENIC PART OF AN ANTIGEN OF M. SOLUBLE TUBERCULOSIS, AND DNA MOLECULES THAT CODIFY SUCH POLYPEPTIDES, EXPRESSION VECTORS THAT UNDERSTAND SUCH MOLECULES OF DNA, CELLS HARDWARE, DIFFERENT MUSCLES

Country Status (2)

Country Link
AR (1) AR018100A1 (en)
ZA (1) ZA991303B (en)

Also Published As

Publication number Publication date
ZA991303B (en) 2000-03-15

Similar Documents

Publication Publication Date Title
CY1113379T1 (en) KDR Peptides and Vaccines Included
AR014514A1 (en) AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE
NO20070618L (en) Compounds and Methods for Immunotherapy and Diagnosis of Tuberculosis.
AR032173A1 (en) CRYPT PROTEINS AND THEIR VARIANTS AS LYMPHOCYTARY EFFECTS AGAINST CANCER
AU656159B2 (en) Cloning and expression of borrelia lipoproteins
NO995689L (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods for their use
ITFI920052A1 (en) PROTEIN EXTRACTED FROM HELICOBACTER PYLORI CYTOTOXIC STRAINS, GENE THAT EXPRESSES IT, USE OF PROTEIN AS VACCINE OR DIAGNOSTIC.
JP2009136300A (en) Porphorymonas gingivalis polypeptide and nucleotide
CA2337100A1 (en) Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same
AR029814A1 (en) MOLECULES MADE WITH CHORDIN 2 AND USES OF THE SAME
AR053372A1 (en) IMMUNOLOGICAL PROTEINS OF LAWSONIA INTRACELLULARIS
CA2461443A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
AR020066A1 (en) A PURIFIED POLYPEPTIDE, USEFUL TO PREVENT TUBERCULOSIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE POLYPEPTIDES AND THE POLYCUCLEOTIDES WHICH CODIFY
CA2432971A1 (en) Polypeptides
PE20240915A1 (en) COMPOSITIONS AND METHODS FOR TREATING FABRY DISEASE
EP1523497B1 (en) Hsp70 from arthrobacter
AR010337A1 (en) ISOLATED NUCLEIC ACID, NUCLEIC ACID MOLECULA, PROBE, RECOMBINANT EXPRESSION VECTOR, CELL, METHOD FOR PRODUCING A POLYPEPTIDE OF H.PYLORI, METHOD FOR DETECTING THE PRESENCE OF A NUCLEIC ACID HELICOBACTER, POLIPE FORMULATION FOR VACCINE
AR018100A1 (en) POLYPEPTIDES THAT UNDERSTAND AN IMMUNOGENIC PART OF AN ANTIGEN OF M. SOLUBLE TUBERCULOSIS, AND DNA MOLECULES THAT CODIFY SUCH POLYPEPTIDES, EXPRESSION VECTORS THAT UNDERSTAND SUCH MOLECULES OF DNA, CELLS HARDWARE, DIFFERENT MUSCLES
AR013801A1 (en) NEW MOLECULES OF ISOLATED NUCLEIC ACID, A HYDROLASSE HYDROLASSE EPOXIDE PROTEIN OF ISOLATED HEMATOPHAGO ART, A FORMULATION OF PULGE HYDROLASSE DEEPOXIDE PROTEINS, A THERAPEUTIC COMPOSITION THAT REDUCES HOSPITAL INFRASTAGATION; USE OF SUCH COMPOSITION FOR
WO2001074847A3 (en) T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
Verkuylen et al. Characterization of the mRNA encoding a proline-rich 37-kilodalton glycoprotein from the excretory-secretory products of Trichostrongylus colubriformis
RU2004103078A (en) IMMUNE BINDING MOLECULES INHIBITING SYNCITIAL MERGER OF TROFOBLAST CELLS
AR020318A1 (en) AN ISOLATED POLYNUCLEOTIDIC MOLECULA, AN ISOLATED POLYPEPTIDE CODIFIED BY THE MOLECULA, AN EXPRESSION VECTOR, A TRANSFORMED GUEST CELL, A FUSION PROTEIN, A PHARMACEUTICAL COMPOSITION AND A COMPREHENSIVE VACCINE; METHODS FOR TREATMENT, DETECTION,
HUP9903843A2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
AR037054A1 (en) COMPOSITIONS AND METHODS OF DIAGNOSIS AND THERAPY OF CANCER DE PULMON

Legal Events

Date Code Title Description
FB Suspension of granting procedure